Sorafenib Completed Phase 2 Trials for Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Salivary Gland Cancer / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage IVC Verrucous Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Salivary Gland Cancer / Untreated Metastatic Squamous Neck Cancer With Occult Primary / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVC Salivary Gland Cancer / Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Stage IVC Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Squamous Cell Carcinoma of the Larynx / Recurrent Salivary Gland Cancer / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Tongue Cancer / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Verrucous Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Verrucous Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IVB Verrucous Carcinoma of the Larynx Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00939627Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
NCT00096512S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer